$330 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 80 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | Fresh Tracks Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.00% | – | |
| VRAY | Exit | Viewray Incequities | $0 | – | -100,000 | -100.0% | -0.01% | – |
| GKOS | Exit | Glaukos Corpequities | $0 | – | -1,000 | -100.0% | -0.02% | – |
| PIRS | Exit | Pieris Pharmaceuticals Incequities | $0 | – | -961,338 | -100.0% | -0.05% | – |
| GLUE | Exit | Monte Rosa Therapeutics Incequities | $0 | – | -31,156 | -100.0% | -0.07% | – |
| FGEN | Exit | FibroGen Inccall | $0 | – | -100,000 | -100.0% | -0.08% | – |
| CLDX | Exit | Celldex Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.10% | – |
| IMTX | Exit | Immatics Nvequities | $0 | – | -30,715 | -100.0% | -0.11% | – |
| Exit | Jasper Therapeutics Incequities | $0 | – | -500,000 | -100.0% | -0.21% | – | |
| PTGX | Exit | Protagonist Therapeutics Incequities | $0 | – | -25,000 | -100.0% | -0.21% | – |
| Exit | Ventyx Biosciences Incequities | $0 | – | -25,000 | -100.0% | -0.25% | – | |
| BBIO | Exit | Bridgebio Pharma Incequities | $0 | – | -50,000 | -100.0% | -0.27% | – |
| ALLK | Exit | Allakos Incequities | $0 | – | -200,000 | -100.0% | -0.27% | – |
| RETA | Exit | Reata Pharmaceuticals Incequities | $0 | – | -12,500 | -100.0% | -0.39% | – |
| CUE | Exit | Cue Biopharma Incequities | $0 | – | -403,402 | -100.0% | -0.46% | – |
| AMAM | Exit | Ambrx Biopharma Incequities | $0 | – | -100,000 | -100.0% | -0.51% | – |
| INCY | Exit | Incyte Corpequities | $0 | – | -34,110 | -100.0% | -0.66% | – |
| ACRS | Exit | Aclaris Therapeutics Incequities | $0 | – | -219,229 | -100.0% | -0.70% | – |
| PHAT | Exit | Phathom Pharmaceuticals Incequities | $0 | – | -200,000 | -100.0% | -0.89% | – |
| ANIP | Exit | ANI Pharmaceuticals Incequities | $0 | – | -54,041 | -100.0% | -0.90% | – |
| PHVS | Exit | Pharvaris NVequities | $0 | – | -200,000 | -100.0% | -0.94% | – |
| VKTX | Exit | Viking Therapeutics Incequities | $0 | – | -258,595 | -100.0% | -1.30% | – |
| Exit | Nuvalent Incequities | $0 | – | -115,067 | -100.0% | -1.50% | – | |
| Exit | MoonLake Immunotherapeuticsequities | $0 | – | -200,000 | -100.0% | -3.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SILVERARC CAPITAL, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.